Quarterly Activities Report and Appendix 4C
Filed with ASX · · 7 pages · English
Summary by 6ix AI
Starpharma also reported a cash balance at the end of the quarter and noted a substantial increase in customer receipts compared to the previous year, reflecting strong revenue growth from its products. The filing outlines the company's ongoing efforts to enhance its oncology portfolio and expand its market presence through strategic collaborations and product sales.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- DEP milestone triggers partner option fee
- Positive DEP HER2-Lu preclinical data support Phase 1 entry
- DEP radiopharmaceutical data supports patent application
- FDA confirms path to DEP HER2 first-in-human study
- Half Yearly Report and Accounts
Later from Starpharma
- Fully Underwritten Entitlement Offer to Raise $32 Million
- Entitlement Offer Investor Presentation
- Successful Completion of $32 million Entitlement Offer
- Preliminary Final Report
- FY26 Key Financial Results and Annual Report
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma